Etrasimod administration

Preclinical

Etrasimod administration is one of 2 therapeutic programs targeting Ulcerative Colitis (Disorder). It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

Ulcerative Colitis (disorder)Recruiting

Ulcerative Colitis (disorder)Preclinical

Recruiting

Competition

Competitive Landscape

1 competitor in Ulcerative Colitis (disorder)

#DrugCompanyPhaseTrials

Velsipity

Pfizer

Preclinical

1 2

Etrasimod administration

SShowa Inan General Hospital

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2027

PreclinicalRecruiting

Ulcerative Colitis (disorder)

NCT07243639

Clinical

Trials by Indication[1]

Ulcerative Colitis (Disorder)1 trial

A Prospective Study on the Efficacy and Safety of a Novel Oral Drug, Etrasimod, in Elderly Patients With Ulcerative Colitis

Recruiting·SShowa Inan General Hospital·Preclinical·NCT07243639·30 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Etrasimod administration. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for Etrasimod administration. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Showa Inan General Hospital company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Preclinical[1]
Company: SShowa Inan General Hospital

Etrasimod administration

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q3 2027

Trials by Indication[1]

Ulcerative Colitis (Disorder)1 trial

References

Drug Info

Quick Facts

Related News